Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Hassell (OPP1153692): Vaccine Product Development Center |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Phase I/II |
| Species: | Human |
| Stage: | In progress |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
Safety and pharmacokinetics of the combination broadly neutralizing antibodies, 3BNC117-LS-J and 10-1074-LS-J, in healthy American and African adults
Description
CAVD 809 (IAVI C100) is a Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics of bnAbs, 3BNC117-LS-J and 10-1074-LS-J, when given alone and in combination, intravenously (IV) or subcutaneously (SC).
Sign in to see full information about this study and to download study data.
Products
Saline Formulation buffer 3BNC117-LS-J 10-1074-LS-JIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.